Le financement renforce l’approbation de l’exemption pour dispositif expérimental (IDE) aux États-Unis, l’avancement clinique coronarien et l’expansion des applications périphériques sous le genou (BTK).

SANTA CLARA, Californie, 2 juin 2026 — Advanced NanoTherapies, Inc. (ANT), une société de technologie médicale au stade clinique qui se consacre à l’amélioration des résultats pour les patients atteints de maladies coronariennes et artérielles périphériques, a annoncé aujourd’hui la clôture d’un financement de série B sursouscrit d’un montant total de plus de 31 millions de dollars. Ce tour de table a été effectué conjointement par un investisseur stratégique dont l’identité n’a pas été révélée et par S3 Ventures, avec la participation du fonds T45 et d’investisseurs nouveaux et existants.

ANT redéfinit le paradigme de l’intervention vasculaire avec une nanoparticule de nouvelle génération à double médicament (paclitaxel et sirolimus) sur un ballon percutané. Cette approche vise à optimiser les effets thérapeutiques tout en favorisant une réponse vasculaire plus prévisible et durable par rapport aux ballons enrobés de médicaments de première génération contenant un seul médicament cristallin.

« Ce financement arrive à un moment critique dans le domaine de l’intervention vasculaire. Les ballons de première génération enrobés d’un seul médicament gagnent du terrain sur le marché américain, mais ils continuent d’exposer les limites de l’administration passive de médicaments cristallins », a déclaré Marwan Berrada-Sounni, PDG d’ANT. « ANT est particulièrement bien placé pour faire progresser le domaine grâce à une approche différenciée de la thérapie vasculaire locale basée sur les nanoparticules, qui aurait dû être mise en œuvre depuis longtemps. »

« La resténose après une ICP (intervention coronarienne percutanée) reste un défi clinique important, en grande partie dû à la prolifération cellulaire au niveau du site de traitement. Cette nouvelle plateforme vise à délivrer deux médicaments simultanément sur le site de la lésion en utilisant des nanoparticules fonctionnalisées, ce qui permet une rétention locale durable du médicament à des doses plus faibles », a déclaré Rishi Puri, MD, cardiologue interventionnel, Cleveland Clinic.

Cette technologie, sous licence exclusive de la Cleveland Clinic, est conçue comme une plateforme entièrement biodégradable et agnostique du point de vue des médicaments, pour des applications coronariennes, périphériques et vasculaires futures. SirPlux Duo, le programme phare d’ANT, a reçu la désignation de percée de la FDA et n’est pas encore approuvé pour une utilisation commerciale.

« SirPlux Duo permet une double administration de médicaments avec une absorption cellulaire contrôlée et une rétention tissulaire soutenue, générant une puissance plus élevée à des doses plus faibles, réduisant la charge particulaire en aval et préservant les options de traitement futures pour les maladies coronariennes et vasculaires périphériques », a déclaré Azeem Latib, MD, Directeur médical, Intervention cardiaque structurelle, Montefiore Einstein. « La création d’une nouvelle catégorie de ballon enrobé de médicament utilisant deux médicaments plutôt qu’un seul constitue un bond en avant dans le domaine de l’intervention vasculaire, offrant des résultats cliniques durables qui ne sont pas inférieurs à ceux des stents à élution de médicaments, tout en maintenant la stratégie d’intervention consistant à ne rien laisser derrière soi. »

L’expérience clinique confirme cette approche, y compris une première étude chez l’homme portant sur 28 patients en Australie, en République dominicaine et en Nouvelle-Zélande, avec un suivi de deux ans qui n’a révélé aucun nouvel échec du traitement. En outre, en Espagne, des chercheurs mènent actuellement une étude sur 30 patients, conçue pour refléter le protocole pivot américain, qui fait actuellement l’objet d’un suivi. L’ensemble de ces données devrait constituer une base solide pour l’exécution des études pivots américaines.

« Ce financement valide la force de la plateforme d’ANT et l’élan donné à la science, à l’exécution clinique et à la préparation réglementaire », a déclaré Brian R. Smith, directeur général de S3 Ventures. « Grâce à l’expérience clinique acquise dans le cadre de deux études sur les maladies coronariennes et à une voie réglementaire claire aux États-Unis, ANT est bien placée pour passer à l’étape de l’exécution pivotale et pour offrir un traitement réellement différencié aux patients qui ont besoin de meilleures options. »

Les prochaines étapes concernent l’augmentation de la production pour répondre aux exigences de la FDA en matière d’IDE pour les dispositifs des programmes coronaires et périphériques. Les demandes d’autorisation IDE aux États-Unis porteront sur deux indications coronariennes : la resténose du stent et les lésions de novo des petits vaisseaux. Parmi les autres priorités figurent l’achèvement du dossier d’essai et la soumission d’une demande d’exemption pour dispositif expérimental pour une étude de faisabilité précoce sous le genou (BTK) aux États-Unis, la poursuite d’un accord d’essai clinique pivot avec la FDA et l’identification de sites cliniques en dehors des États-Unis en tant que centres de recrutement pivot précoces.

A propos d’Advanced NanoTherapies, Inc. (ANT)
Advanced NanoTherapies, une société du portefeuille de T45 Labs, développe une plateforme différenciée de nanoparticules fonctionnalisées pour l’administration locale de deux médicaments lors d’interventions par cathéter. Le programme phare de la société, SirPlux Duo, établit une nouvelle catégorie de thérapie par ballon enrobé de médicament en délivrant activement et simultanément deux médicaments synergiques aux cellules vasculaires, ce qui permet une administration contrôlée et soutenue de deux médicaments au niveau de la lésion. La technologie est sous licence exclusive de la Cleveland Clinic et fait l’objet d’une évaluation clinique dans le cadre de l’étude ADVANCE-DUO. SirPlux Duo a reçu la désignation de percée de la FDA et est un dispositif expérimental dont l’utilisation commerciale n’a pas encore été approuvée.

À propos de S3 Ventures
Fondée en 2005, S3 Ventures est l’une des sociétés de capital-risque les plus importantes et les plus anciennes du Texas. Soutenue par une famille philanthropique disposant d’une fondation de plusieurs milliards de dollars, elle met à la disposition des fondateurs visionnaires le capital patient et les ressources nécessaires pour développer des entreprises extraordinaires à fort impact dans les domaines des affaires et des technologies de la santé. Avec plus d’un milliard de dollars d’actifs sous gestion, ils dirigent des investissements en phase d’amorçage, de série A et de série B, allant de 500 000 à 10 millions de dollars, avec la capacité d’investir plus de 20 millions de dollars au cours de la vie d’une entreprise. Pour en savoir plus, consultez le site www.s3vc.com.

Logo – https://mma.prnewswire.com/media/2991562/Advanced_NanoTherapies_Logo.jpg
Photo – https://mma.prnewswire.com/media/2991563/Advanced_NanoTherapies_SirPlux_Duo.jpg

Growth capital backed by BlackRock and existing investor Stonehage Fleming as company surpasses 100 institutional partners across 30 states

GREENVILLE, Texas, June 2, 2026 — BibliU, the integrated academic and campus store solutions provider, today announced $55 million in new funding from BlackRock, existing investor Stonehage Fleming, and other parties.

The announcement comes as BibliU surpasses $100 million in annual revenue, driven by compound annual growth in excess of 100% over the past two years and a rapidly expanding base of institutional partnerships across the United States.

SERVING MORE STUDENTS, IN MORE STATES, EVERY SEMESTER

BibliU partners with colleges and universities as a fully integrated campus retail and course materials provider, combining managed campus store operations with its proprietary digital learning platform. Unlike traditional providers that rely on multiple third parties, BibliU delivers a single accountable partnership across retail, eCommerce, course material delivery, and publisher relationships. Institutions benefit from greater operational alignment, transparency, and flexibility, while students gain more affordable Day 1 access to required materials alongside a modern retail experience designed to strengthen engagement and campus connection.

With more than 100 institutional partners across 30 states, BibliU continues to expand its presence across higher education through long-term campus partnerships and statewide system relationships. Recent additions include the Kentucky Community and Technical College System, serving 16 colleges and representing BibliU’s first statewide system partnership and entry into Kentucky, as well as the University of Texas Rio Grande Valley.

The company has also continued to build significant momentum in North Carolina, where 13 community colleges have transitioned to BibliU. Each new partnership reflects a shared commitment to improve retail experiences and support student success through more effective campus solutions.

This capital enables BibliU to continue meeting that demand: investing in inventory, platform development, and the operational capacity to serve new and existing partners at the highest level.

“Several years ago, we made the deliberate decision to expand beyond digital course material delivery and build a truly vertically integrated model — one that combines our technology platforms with full-service campus retail operations,” said Dave Sherwood, CEO of BibliU. “The acquisition of Texas Book Company was the catalyst for that vision and enabled us to build something no other provider in this market offers at our scale. We now have the best team in the industry, are winning new institutional partners across new states every semester, and are doing it with a clear focus on profitable growth. The support from BlackRock and Stonehage Fleming reflects confidence in both our strategy and trajectory. We are excited about what comes next for our partners and their students.”

CONTINUED INVESTOR CONFIDENCE

BlackRock has been a financing partner to BibliU since the Texas Book Company acquisition, the transaction that launched BibliU Campus and established BibliU’s hybrid digital-and-retail model in the US. Their continued support reflects multi-year confidence in BibliU’s execution and long-term vision.

Stonehage Fleming, the multi-family office and long-standing BibliU investor, has made a further commitment through a convertible investment, reflecting continued conviction in BibliU’s model and management team.

“We first invested in BibliU because we believed in the team and the scale of the opportunity in higher education. Everything that has followed — the launch and expansion into the US market, the Texas Book Company acquisition, the growth to over 100 institutional partners, surpassing $100 million in revenue — has reinforced that conviction. BibliU is not just growing, they are doing it in a way that genuinely improves outcomes for students and institutions alike.”

— Richard Hill, Head of Private Markets at Stonehage Fleming

About BibliU
BibliU is the only vertically integrated campus store and course materials partner combining proprietary digital technology, innovative access programs, flexible billing models, and end-to-end retail operations. Serving more than 170 colleges and universities globally, BibliU enables institutions to deliver affordable, accessible course materials on Day 1 while simplifying operations, increasing transparency, and advancing student success. Learn more at bibliu.com.

SOURCE BibliU

Mit einem gesicherten Auftragsvolumen von über 1 Milliarde US-Dollar beschleunigt die Finanzierung den Ausbau des Lagerbestands, um der steigenden Nachfrage nach einer offenen, herstellerunabhängigen und heterogenen KI-Infrastruktur gerecht zu werden 

RA’ANANA, Israel, 2. Juni 2026 — DriveNets, ein führender Anbieter von groß angelegten Netzwerklösungen, gab heute bekannt, dass das Unternehmen eine Serie-D-Finanzierungsrunde in Höhe von 410 Millionen US-Dollar abgeschlossen hat und damit insgesamt 1 Milliarde US-Dollar an Kapital eingeworben hat. Mit einem Auftragsbestand von über 1 Milliarde US-Dollar und einem seit 2025 positiven Cashflow wird das Unternehmen die zusätzlichen Finanzmittel dazu nutzen, seine Lagerbestände aufzustocken, um seine wachsende Pipeline an KI-Fabric-Lösungen zu unterstützen und seine heterogenen KI-Infrastrukturlösungen auszubauen. Die Finanzierungsrunde wurde von Bessemer Venture Partners und Atreides Management angeführt. Zu den bestehenden Investoren Pitango und D1 Capital Partners gesellten sich die neuen Investoren AMD und Red Dot Capital.

Seit der Gründung des Unternehmens vor zehn Jahren hat sich die Network Cloud von DriveNets zum maßgeblichen Netzwerk für die weltweit größten Telekommunikationsunternehmen entwickelt. Die auf derselben technischen Grundlage aufbauende, Ethernet-basierte KI-Infrastruktur von DriveNets unterstützt groß angelegte KI-Infrastrukturen, die von Forschungslabors, Hyperscalern, NeoClouds und großen Unternehmen aufgebaut werden. Das Unternehmen arbeitet aktuell mit führenden KI-Anbietern wie AMD, Broadcom und anderen zusammen, um die Integration zwischen Netzwerk- und Rechenkomponenten in KI-Umgebungen mit mehreren Anbietern zu verbessern und so die Cluster-Leistung sowie die GPU-Auslastung zu maximieren, was zu einer erheblichen Verbesserung der Token-Ökonomie führt. Zudem arbeitet das Unternehmen bei den Markteinführungsaktivitäten mit Dell, Supermicro und anderen Systempartnern zusammen.

„Diese Finanzierungsrunde ist ein entscheidender Schritt für den Ausbau unseres Unternehmens, um der steigenden Nachfrage nach groß angelegter KI-Infrastruktur gerecht zu werden”, sagte Ido Susan, Geschäftsführer und Mitbegründer von DriveNets. „Die derzeit teuerste ungenutzte Ressource weltweit ist eine GPU, die auf das Netzwerk wartet. Wir setzen unser jahrzehntelanges Know-how im Bereich Hochleistungsnetzwerke ein, um unseren Kunden zu ermöglichen, eine höhere Auslastung zu erzielen, die Kosten pro Workload zu senken und ihre KI-Betriebsabläufe effizient zu skalieren – und zwar auf jedem KI-Beschleuniger ihrer Wahl.”

„Die KI-Infrastruktur tritt in eine neue Ära offener, integrierter Systeme ein, in der Rechenleistung, Netzwerktechnologie und Software gemeinsam skalieren”, sagte Vamsi Boppana, Senior-Vizepräsident für KI bei AMD. „Unsere Unterstützung der Serie-D-Finanzierungsrunde von DriveNets spiegelt unser gemeinsames Engagement wider, KI-Workloads mithilfe von AMD Instinct-Beschleunigern und der leistungsstarken Fabric von DriveNets auf einer offenen Infrastruktur effizient zu skalieren und damit offene, auf Standards basierende KI-Rechenzentren voranzubringen.”

Das Problem der teuersten ungenutzten Ressource angehen – eine GPU, die auf das Netzwerk wartet

Die KI-Fabric-Lösungen von DriveNets basieren auf Standard-Ethernet und unterstützen Scale-up-, Scale-out- und Scale-across-Architekturen sowie Front-End- und Speicheranbindungen für groß angelegte KI-Cluster.  Sie lösen zwei grundlegende Probleme, mit denen KI-Infrastrukturen heute konfrontiert sind: große GPU-Cluster, die aufgrund von Netzwerkengpässen und Zuverlässigkeitsproblemen nicht mit voller Effizienz arbeiten, sowie lange Cluster-Inbetriebnahmezeiten („idle Capex”), insbesondere in Umgebungen mit mehreren Anbietern.

Die leistungsstarke KI-Fabric von DriveNets beseitigt Netzwerkengpässe durch durchgängige Netzwerkoptimierungen über den gesamten KI-Stack hinweg, einschließlich gemeinsamer Kommunikationsbibliotheken, Transportprotokolle, Netzwerkkarten, der Netzwerk-Fabric und der Orchestrierung auf Systemebene. Einige dieser Optimierungen werden in Zusammenarbeit mit führenden Anbietern von KI-Beschleunigern entwickelt, wie beispielsweise die kürzlich veröffentlichte, validierte Referenzarchitektur für AMD-DriveNets-basierte Cluster, die die GPU-Auslastung maximiert, die Kosten pro Token senkt und eine schnelle Bereitstellung sowie eine effiziente End-to-End-Skalierung ermöglicht.

„Vor dem Hintergrund, dass KI-Systeme eine noch nie dagewesene Größenordnung erreichen, ist die Leistungsfähigkeit der zugrunde liegenden Netzwerkstruktur zu einem entscheidenden Faktor für die Wirtschaftlichkeit der KI geworden”, sagte Charlie Kawwas, Vorsitzender der Semiconductor Solutions Group bei Broadcom. „Die KI-Halbleiter- und Ethernet-Switching-Lösungen von Broadcom bieten in Kombination mit der leistungsstarken Fabric von DriveNets die Skalierbarkeit und Effizienz, die moderne KI-Workloads erfordern. Diese Zusammenarbeit verdeutlicht, wie offenes Ethernet zur Grundlage für KI-Rechenzentren der nächsten Generation wird.”

„Der Markt für KI-Netzwerke ist auf dem besten Weg, bis zum Ende des Jahrzehnts die 200-Milliarden-Dollar-Marke zu überschreiten, angetrieben durch den Wandel von Stacks einzelner Anbieter hin zu Multi-Vendor- und später heterogenen KI-Infrastrukturen. DriveNets tritt in diese Phase mit einer starken Kombination ein – der Zuverlässigkeit eines Tier-1-Dienstleisters, einem validierten AMD-Referenzdesign und der Lagerbestandslage, um einen von Lieferengpässen geprägten Markt zu beliefern. Dadurch ist das Unternehmen gut positioniert, da offenes Ethernet zur Grundlage der KI-Infrastruktur der nächsten Generation wird”, sagte Alan Weckel, Gründer und Technologieanalyst der 650 Group.

DriveNets – ein wegweisender Akteur im Bereich der heterogenen KI

Die jüngste Verlagerung der Ausgaben für KI-Infrastruktur vom Training hin zur Inferenz soll die Einführung heterogener KI-Architekturen vorantreiben, die die Infrastrukturkosten senken und die Energieeffizienz optimieren.

Eine heterogene KI-Architektur nutzt mehrere KI-Beschleuniger verschiedener Anbieter innerhalb desselben Clusters, wobei jeder Beschleuniger für eine andere Phase oder Aufgabe im Rahmen des KI-Trainings- oder Inferenzprozesses optimal geeignet ist. Die Rechenressourcen im Cluster werden so koordiniert, dass sie die bestmögliche Gesamtleistung und Energieausnutzung bieten, um die Kosten pro Million Token zu senken und die Anzahl der Token pro Watt zu maximieren.

Die KI-Fabric von DriveNets ist aufgrund ihrer Fähigkeit, eine Full-Stack-Optimierung für jeden KI-Beschleuniger im Cluster durchzuführen, in einzigartiger Weise darauf ausgerichtet, heterogene KI-Umgebungen mit Komponenten verschiedener Hersteller zu unterstützen, wodurch die Leistung und Auslastung des gesamten Clusters maximiert werden.

„Jeder Wandel in der Computing-Branche bringt einen neuen Netzwerkriesen hervor. Cisco hat das Internet vernetzt. Arista hat die Cloud vernetzt. NVIDIA hat die KI eines einzelnen Anbieters vernetzt. DriveNets vernetzt das, was als Nächstes kommt: heterogene KI”, sagte Adam Fisher, Partner bei Bessemer Venture Partners. „Aus diesem Grund hat BVP die Serie-D-Finanzierungsrunde von DriveNets in Höhe von 410 Millionen US-Dollar angeführt, einem bestehenden Portfoliounternehmen, das wir bereits seit seiner Serie-A-Finanzierung unterstützen.”

Informationen zu DriveNets

DriveNets ist ein führender Anbieter von groß angelegten Netzwerklösungen für KI-Infrastrukturen und Service Provider. Die dezentrale Netzwerkarchitektur des Unternehmens verändert die Wirtschaftlichkeit groß angelegter Infrastrukturen und maximiert gleichzeitig Leistung, Auslastung und betriebliche Effizienz. Die leistungsstarke KI-Fabric maximiert die GPU-Auslastung und beschleunigt die Bereitstellung durch eine durchgängige Optimierung des KI-Stacks, was zu einer höheren Anzahl von Tokens pro Sekunde und geringeren Kosten pro Token führt. Die Lösungen von DriveNets bilden die Grundlage für Produktionsnetzwerke globaler Tier-1-Betreiber wie AT&T und Comcast und ermöglichen die Skalierung herstellerübergreifender KI-Infrastrukturen in Labors für Grundmodelle, NeoClouds und Unternehmen. Weitere Informationen erhalten Sie unter https://www.drivenets.com

Logo – https://mma.prnewswire.com/media/1657406/5997029/DriveNets_Logo.jpg

Financing supports the approval of U.S. Investigational Device Exemption (IDE), coronary clinical advancement, and expansion into below-the-knee peripheral (BTK) applications.

SANTA CLARA, Calif., June 2, 2026 — Advanced NanoTherapies, Inc. (ANT), a clinical-stage medtech company dedicated to improving outcomes for patients with coronary and peripheral artery disease, today announced the closing of an oversubscribed Series B financing totaling more than $31 million. The round was co-led by an undisclosed strategic investor and S3 Ventures, with participation from the T45 Fund and new and existing investors.

ANT is redefining the vascular intervention paradigm with a next-generation dual-drug (paclitaxel and sirolimus) nanoparticle on a percutaneous balloon platform. This approach aims to maximize therapeutic effects while promoting a more predictable, sustained vascular response compared with first-generation drug-coated balloons (DCBs) with a crystalline single-drug.

“This financing milestone arrives at a pivotal moment in vascular intervention. First-generation single drug DCBs are gaining traction in the U.S. market, but they continue to expose the limitations of passive crystalline drug delivery,” said Marwan Berrada-Sounni, CEO of ANT “ANT is uniquely positioned to advance the field through a differentiated nanoparticle-enabled approach to local vascular therapy, which is long overdue.”

“Restenosis after PCI (percutaneous coronary intervention) continues to be a meaningful clinical challenge, largely driven by cell proliferation at the treatment site. This novel platform aims to deliver two drugs simultaneously to the lesion site using functionalized nanoparticles, enabling sustained local drug retention at lower doses,” said Rishi Puri, MD, interventional cardiologist, Cleveland Clinic.

The technology is exclusively licensed from Cleveland Clinic and built as a drug-agnostic, fully biodegradable platform for coronary, peripheral, and future vascular applications. SirPlux Duo, ANT’s lead program, has received FDA breakthrough designation and is not yet approved for commercial use.

“SirPlux Duo enables dual-drug delivery with controlled cellular uptake and sustained tissue retention, generating higher potency at lower doses, reducing downstream particulate burden, and preserving future treatment options across coronary and peripheral vascular disease,” said Azeem Latib, MD, Medical Director, Structural Heart Intervention, Montefiore Einstein. “The creation of a new DCB category using two rather than one drug is a leapfrogging moment in vascular intervention, providing sustainable clinical outcomes that are non-inferior to those of drug-eluting stents while maintaining the intervention strategy of leaving nothing behind.”

Clinical experience supports this approach, including a first-in-human study of 28 patients across Australia, the Dominican Republic, and New Zealand, with a two-year follow-up showing no new treatment failures. In addition, in Spain, investigators are conducting an ongoing 30-patient study designed to mirror the U.S. pivotal protocol, which is currently in follow-up. Together, these data sets are expected to create a strong foundation for U.S. pivotal execution.

“This financing validates the strength of ANT’s platform and the momentum built across science, clinical execution, and regulatory readiness,” said Brian R. Smith, Managing Director at S3 Ventures. “With clinical experience across two coronary studies and a clear U.S. regulatory path, ANT is well positioned to move toward pivotal execution and to bring a truly differentiated therapy to patients needing better options.”

Next steps include scaling up manufacturing to meet FDA IDE requirements for devices across both coronary and peripheral programs. U.S. IDE submissions will advance two coronary indications: in-stent restenosis and small-vessel de novo lesions. Additional priorities include completing the testing package and IDE submission for a U.S. BTK early feasibility study, pursuing a pivotal clinical trial agreement with the FDA, and identifying clinical sites outside the U.S. as early pivotal enrollment centers.

About Advanced NanoTherapies, Inc. (ANT)
Advanced NanoTherapies, a T45 Labs portfolio company, is developing a differentiated functionalized nanoparticle platform for local, dual-drug delivery during catheter-based interventions. The company’s lead program, SirPlux Duo, establishes a new category in drug-coated balloon (DCB) therapy by actively delivering two synergistic drugs simultaneously to vascular cells, enabling controlled, sustained dual-drug delivery at the lesion site. The technology is exclusively licensed from Cleveland Clinic and is under clinical evaluation in the ADVANCE-DUO study. SirPlux Duo received FDA breakthrough designation and is an investigational device that has not yet been approved for commercial use.

About S3 Ventures
Founded in 2005, S3 Ventures is one of the largest and longest-serving venture capital firms in Texas. Backed by a philanthropic family with a multi-billion-dollar foundation, they empower visionary founders with the patient capital and proper resources required to grow extraordinary, high-impact companies in Business and Healthcare Technology. With over $1 billion in assets under management, they lead investments in Seed, Series A, and Series B rounds, ranging from $500,000 to $10 million, with the capacity to invest over $20 million in a company’s lifetime. To learn more, visit www.s3vc.com.

Logo – https://mma.prnewswire.com/media/2991562/Advanced_NanoTherapies_Logo.jpg
Photo – https://mma.prnewswire.com/media/2991563/Advanced_NanoTherapies_SirPlux_Duo.jpg

Alitheon®, the advanced optical-AI pioneer, today announced the closing of the round led by Emerald Technology Ventures, with significant participation from eBay Ventures and continued support from existing investors.

BELLEVUE, Wash., June 2, 2026 — The capital accelerates global deployment of Alitheon’s FeaturePrint® technology—a category-defining solution backed by 55+ issued patents.

The industry has long relied on barcodes, tags, and stickers, but these external proxy markers can be damaged, detached, or counterfeited. Standard machine learning only identifies objects at a class level, recognizing a generic part rather than a specific asset. Alitheon renders these obsolete by capturing the inherent surface details of an object to create a unique, unforgeable identity—true 1-to-1 serialization without adding anything to the product.

The result is biometrics for things: a Zero Trust framework where no item is assumed authentic until its digital fingerprint is verified via a standard camera. With nothing added, there is no marker for bad actors to spoof, ensuring an unbreakable link between the physical object and its digital record.

“Securing support from such powerhouses proves the world is ready for digital-first serialization, provenance, and traceability,” said Roei Ganzarski, CEO of Alitheon. “We aren’t just identifying goods; we are powering the trust layer of the global economy, providing a level of security that additives and standard AI simply cannot match.”

“At Emerald, we look for technologies that solve fundamental industrial challenges at scale,” said Gina Domanig, Managing Partner at Emerald Technology Ventures. “Alitheon’s ability to provide 1-to-1 serialization without the need for labels or tags is a game-changer for global supply chains. By establishing a ‘Zero Trust’ framework for physical goods, Alitheon is providing the essential data integrity required for the future of automated manufacturing and logistics.”

“As recommerce continues to grow, trust and provenance are becoming increasingly important across high-value categories,” added Henri Jaanimägi, Global Head of eBay Ventures. ” Alitheon’s ‘biometrics for things’ represents an important step forward in the broader trust infrastructure needed to support more transparent and confident buying and selling experience.”

This round positions Alitheon as the definitive leader in “Physical-to-Digital” identity, offering the essential technology to secure global trade.

Learn more about the companies by visiting the websites at:

https://alitheon.com;

https://emerald.vc;

https://www.ebayinc.com/ebay-ventures/

Contact: [email protected]

SOURCE Alitheon

New monthly Zoom series where founders and operators across the Bonfire portfolio share what’s actually working in AI, and stay a step ahead, together

SAN DIEGO and LOS ANGELES, June 2, 2026 — Wildfire Systems, a financial technology platform powering loyalty and reward programs, and Bonfire Ventures, a seed-stage venture capital firm backing AI-native, B2B technology companies, today announced the launch of AI Club: A Bonfire x Wildfire Show-and-Tell, a monthly series bringing together innovators, entrepreneurs, and curious minds to share what they are building, testing, and learning with artificial intelligence. The series starts June 5, 2026, 10:00 – 11:15am PT, via Zoom, and sessions will be held on the first Friday of each month.

AI Club is designed as a low-pressure, high-value gathering where participants share real work projects, personal experiments, workflow hacks, favorite tools, demos, or simply their curiosity. Open to leaders and employees across all Bonfire portfolio companies and friends of the Bonfire and Wildfire communities, the series is built on a simple premise: think book club, but for AI.

The series reflects a shared conviction between Wildfire and Bonfire that the most meaningful AI progress often happens in informal, peer-to-peer settings where practitioners compare notes, share failures alongside wins, and build on each other’s ideas. By connecting two communities at the forefront of fintech, commerce, and venture-backed software, AI Club aims to accelerate practical AI adoption across the startup ecosystem.

“AI is moving fast enough that the most valuable thing any of us can do to drive innovation is compare notes in real time,” said Tristan Barnum, Chief Marketing Officer and Head of AI Innovation at Wildfire Systems. “AI Club is that space. We are building it for the same reason we got into AI ourselves: because sharing what you know makes everyone better, and so often the best ideas come from unexpected places.”

“The Bonfire community is full of founders and operators who are quietly building some of the most interesting AI applications we have seen,” said Deb Goldstein, Head of Marketing and Platform at Bonfire Ventures. “AI Club gives them a recurring forum to surface that work, learn from peers across industries, and stay connected to what is actually working on the ground. We are thrilled to build this alongside the Wildfire team.”

Attendance is by invitation, and anyone can visit https://www.wildfire-corp.com/ai-club-invite to request an invitation.

About Wildfire Systems
Wildfire, founded in 2017 in San Diego, powers white-label shopping rewards, retail media, and loyalty programs for financial services and technology partners. Its platform rewards consumers with cashback, coupons, and other benefits, driving sales for 50,000+ merchant programs in over 50 countries. Wildfire’s AI platform, RevenueEngine, monetizes product and brand mentions within content. Ranked among the top fastest-growing companies in the Inc. 5000 in 2023 and 2024, and 2025. Learn more at wildfire-corp.com.

About Bonfire Ventures
Bonfire Ventures is a leading seed-stage venture capital firm backing AI-native B2B technology companies. With more than $1B in assets under management and deep experience helping founders navigate major technology shifts, Bonfire leads seed rounds and partners closely with a small number of companies each year, supporting founders from the earliest stages through scale. The firm’s focused model gives founders access to senior, hands-on partners who bring pattern recognition, operating experience, and trusted support when the path forward is not obvious.

SOURCE Wildfire Systems

HUNTINGTON BEACH, Calif., June 2, 2026 — Mach Industries, a leading defense manufacturer building advanced unmanned systems for modern defense, today announced it has raised $300 million in Series C funding. The new capital will accelerate execution of existing government contracts, talent acquisition, product development, and the expansion of Forge, the company’s flexible manufacturing network.

The round was led by Infinite Capital and Ribbit Capital, valuing the company at $1.8 billion. The new investors join longstanding backers including Bedrock Capital, Sequoia Capital, and Khosla Ventures, an investor group that has supported Mach Industries across multiple stages of its growth.

Mach Industries exists to build next-generation defense systems that preserve an allied American technological edge. As drone warfare accelerates and adversaries field autonomous systems at scale, superiority will belong to those who can develop, manufacture, and deploy faster. Mach Industries is scaling to meet that moment.

“Today’s Series C funding is a powerful accelerator for our mission,” said Founder and CEO Ethan Thornton. “We’re delivering advanced unmanned systems at the pace the threat environment demands, and we’re grateful to our investors for believing in our ability to strengthen American and allied superiority on the battlefield.”

The capital will expand Forge and Mach Propulsion, advance second-generation systems, and deepen partnerships with U.S. Department of War customers, including the Army, Air Force, and SOCOM, as well as allied governments.

“Mach will be vital to the safety and future of free societies” said Nathan Doctor, Founder of Infinite Capital. “As an outlier in defense innovation, Mach has proven with unprecedented speed to flight, production trajectory, and contract success that rebuilding America’s industrial base is of prime importance. The team’s mission-first ethos drives this strategy with urgency and operational discipline.”

Most recently, Mach Industries acquired Exquadrum, now rebranded as Mach Energetics, integrating its energetics systems, engineering team, manufacturing infrastructure, and test facilities to further vertically integrated production and accelerate system delivery. This acquisition enhances testing throughput and enables faster iteration across all platforms, advancing the company’s long-term strategy to build a more independent, resilient, and vertically integrated manufacturing, development, and test base.

“At Ribbit, we partner with teams disrupting the status quo, who see the cracks before anyone else and have the conviction to build something better,” said Micky Malka, Founder of Ribbit Capital. “Ethan and the Mach team are building with urgency, increasingly controlling their supply chain, and refusing to wait for incumbents to catch up. They combine technical depth, execution speed, and a strong sense of duty to country. We’re proud to co-lead this Series C as they build a defining company.”

Over the past twelve months, Mach Industries has scaled across every dimension of the business. The company now operates five active vehicle programs: Viper, a jet-powered vertical take-off, one way vehicle; Glide, a high-altitude strike glider; Stratos, an airborne surveillance platform; Dart, a low-cost counter-drone interceptor; and Pike, a long-range strike munition built for large-scale deployment, with production expected to begin on at least three systems this year.

To support this next phase of growth, Mach has strengthened its executive team with senior technical, operational, and government engagement leaders who will help drive system development, manufacturing scale, and long-term strategic initiatives. Together, these milestones mark Mach’s transition from rapid development to scaled production and deployment.

About Mach Industries
Founded in 2023, Mach Industries is a defense manufacturing company headquartered in Huntington Beach, California. The company develops advanced unmanned systems and the manufacturing infrastructure to scale their production. By vertically integrating weapons, propulsion, and manufacturing, Mach delivers the speed, adaptability, and resilience required to preserve the allied edge in an increasingly contested world. For more information, please visit us at machindustries.com and follow us on LinkedIn and X.

Media Contact:
[email protected]

SOURCE Mach Industries

Funding Comes on the Heels of Novellia Powering Research for the World’s Largest Drugmakers, Signing Several Seven-Figure Contracts, and the Launch of Its Patient-Facing Mobile App

NEW YORK, June 2, 2026 — Novellia, the only real-world data company built entirely on information patients choose to contribute to medical research, today announced an $18 million Series A led by Spark Capital with participation from Khosla Ventures, Acrew Capital, Bling Capital, and TMV, bringing Novellia’s total funding to $28 million. Building on this momentum, Novellia is also launching its patient-facing mobile app, an extension of its award-winning online platform that allows individuals to securely access their complete health history.

Researchers have long depended on real-world data to understand how treatments perform outside clinical trials. But today’s data ecosystem is dominated by third-party brokers stitching together partial datasets from insurance claims and hospital records. The result is a system that costs over $50 billion annually and still leaves out the most important source of truth: the patient.

“Behind every patient is a fragmented, incomplete record of their life,” said Shashi Shankar, Co-Founder and CEO of Novellia. “I watched this up close: first through my grandfather’s cancer journey, and then professionally in pharma, where we were developing therapies without ever seeing the full picture. The system failed patients and researchers at the same time. Novellia changes the course for this whole industry by putting the patient at the center.”

The funding will be utilized to scale Novellia’s AI-powered technology, designed to give patients a free tool to access and organize their complete health history across providers, alongside the opportunity to share it with scientists to advance medical discoveries. Novellia puts this deidentified, anonymized data in the hands of the world’s largest pharmaceutical companies to fuel new cures and treatments, fundamentally changing the course of research and development. Its customers include several of the top 10 pharmaceutical companies and early-stage diagnostics companies.

“I’ve known major pharma companies had data that was too old, too slow, and too disconnected from patients,” said Alex Finkelstein, General Partner at Spark Capital. “For a long time, I looked for a company like Novellia. Shashi understood the problem firsthand and built the solution that benefits patients and research. Since Spark led the Series A, Novellia has signed some of the largest companies in the world to seven-figure, multi-year contracts. This is dramatically changing how medicines are developed.”

“Nearly 70% of patients are open to contributing data for medical breakthroughs, but they expect control, transparency, and privacy safeguards,” said Emma Silverman, Partner at TMV. “That gap between willingness and infrastructure is exactly what Novellia solves by creating a new category of patient-consented data that is both more complete and more actionable for research.”

Within 30 seconds, Novellia helps patients with serious and complex conditions find and unify up to 20 years of medical data from disparate hospital systems, doctors’ offices, and labs across the U.S. The sickest patients carry the greatest administrative burden, spending hours tracking down records and repeating their histories to new providers. Novellia eliminates that overhead with its proprietary, AI-powered platform that pulls the data together into a single, user-friendly source to give patients a free, comprehensive record of their health, something most have never had access to. Novellia then analyzes those records using proprietary NLP models that extract signals from unstructured clinical text, including physician notes, lab narratives, and diagnostic reports. This is often the richest and most overlooked layer of the medical record, where clinicians document their reasoning and researchers finally see why decisions were made, turning raw patient data into anonymized, harmonized datasets ready for research.

About Novellia
Novellia, Inc. is a patient data company that helps people find and unify over 20 years of health data in seconds so they can get better care, while accelerating medical breakthroughs. Named one of Digital Health New York’s 10 startups to watch, a 2026 Fierce Outsourcing Award recipient for Innovation in Drug Development, and a 2026 MedTech Breakthrough Award winner for Best Healthcare Data Repository Solution, Novellia is the only real-world data company built entirely on information patients choose to share with research. Novellia is backed by peer-reviewed research presented at medical congresses, including ASCO and SABCS-AACR. To learn more, visit www.novellia.com.

Media Contact:
SolComms
[email protected]

SOURCE Novellia

The targeted proteomic platform company marks its first anniversary in Carlsbad with four commercial partnerships, seven products, BSL-2 equipped lab, and growing adoption across human and animal health markets globally

CARLSBAD, Calif., June 2, 2026 — As laboratories increasingly seek faster, more cost-efficient alternatives to legacy single-analyte testing, demand for scalable multi-analyte proteomic workflows is growing across pharma, reference laboratory, and animal health markets. Today marks one year since Pictor Holdings Inc., a global targeted proteomic platform company founded in New Zealand, opened its U.S. headquarters in Carlsbad, California.

Pictor isn’t just growing. It’s defining the future of how the world detects disease across humans, animals, and the environment. With seven commercial products, four strategic partnerships, a purpose-built laboratory, and an experienced, enhanced U.S. leadership team, the company heads into year two with a growing pipeline and a platform built to become the backbone of multi-analyte workflows in labs around the world.

Year One: Commercial and Operational Highlights

• Expanded its menu to seven commercial off-the-shelf products and secured four strategic partnerships, including a collaboration with a top 20 global pharmaceutical company (name held confidential) and a formalized commercial collaboration with Disease Research Limited (DRL) in New Zealand for the validation and launch of PictVet^® MAP assay across NZ’s dairy and beef sectors
• Built a pipeline of five active partner agreements spanning oncology, animal health, ELISA consolidation, and wellness markets, and published three peer-reviewed studies in Tuberculosis and Frontiers in Veterinary Science.
• Expanded the Carlsbad facility with a purpose-built lab facility, broadening on-site research and development capabilities, and adding expertise across the scientific, commercial, and operational functions.
• Completed a $5M pre-Series A convertible note, supported by long-term shareholders and a significant new U.S. investor
• Welcomed Terry Kelly, PhD, as Chief Operating Officer — bringing 20+ years in assay development, oncology, and neuroscience, a PhD from UCLA, and authorship on 30+ peer-reviewed publications
• Welcomed Tim Shannon as Chief Financial Officer — a 20+ year biotech finance veteran who previously co-led the strategic partnership and follow-on acquisition of Inivata alongside Jamie Platt

“A year ago, we joined the innovative Carlsbad biotech community. We believe the market is eager for accessible targeted proteomic workflows. What the past twelve months have shown us is that the demand is real, the partnerships are real, and the platform performs. Our second year is about scale — more partners, more markets, and more of the science that makes this platform genuinely differentiated.”
— Jamie Platt, PhD, CEO and Co-founder, Pictor Holdings Inc.

Pictor’s targeted proteomic platform analyzes up to 20 protein targets in a single sample in under two hours, at a cost below market. Through the evolving and customizable Pictorial© software and powered by the AI-enabled PictImager® imaging system, the Pictor platform democratizes access to targeted proteomics. The partner-led commercial model is elegantly simple: partners own the customer relationships while Pictor manufactures and earns recurring revenue per test.

“What drew me to Pictor is the gap between what targeted proteomic technology can do and what most labs currently need it to do. Pictor’s platform is built on tried-and-true diagnostic technology but built in a way that allows labs to ask more questions in a single workflow and in a cost-effective way. Building workflows, systems, and partner relationships that can enable labs to expand their current capabilities and make the science accessible at scale. That’s the work I’m here to do.”
— Terry Kelly, PhD, Chief Operating Officer, Pictor Holdings Inc.

“The companies that define the next era of laboratory science will be the ones that solve both the science and the economics simultaneously. Pictor’s platform does that — and the commercial model means that as adoption scales, the business scales with it. That’s a compelling foundation to build on.”
— Tim Shannon, Chief Financial Officer, Pictor Holdings Inc.

To support the next phase of growth, Pictor is targeting a U.S. Series A of up to $30 million. Proceeds will be deployed to scale assay development and manufacturing capabilities, expand the team and patent portfolio, while advancing large-scale translational studies across priority therapeutic areas with a goal of entering licensing stages with multiple partners within the next 12 to 18 months.

Pictor’s Carlsbad laboratory is designed to grow with its partners. As adoption of targeted proteomic workflows expands across human and animal health, Pictor expects to deepen existing partnerships and establish new ones across pharma, reference laboratories, and veterinary markets globally. For partnership inquiries, contact [email protected] or visit www.pictorproteomics.com.

About Pictor Holdings Inc.
Pictor Holdings Inc. is a global targeted proteomic platform company founded in New Zealand and headquartered in Carlsbad, California, with operations in New Zealand, Australia, and India. The company develops multi-analyte proteomic assay solutions for human and animal health research environments, enabling laboratories and biopharma partners to run more analytes, faster, at lower cost. Pictor’s IP portfolio includes 16 patents, five pending, and seven registered trademarks. For more information, visit www.pictorproteomics.com.

Media Contact
Kelly Krueger
Audacity Health on behalf of Pictor Holdings Inc.
415-235-5031
[email protected]
www.pictorproteomics.com

SOURCE Pictor Holdings Inc.